34 results
CORRESP
ALGS
Aligos Therapeutics Inc
22 Dec 22
Correspondence with SEC
12:00am
Steatohepatitis (“NASH”) targets and up to one additional liver-based cardiometabolic and/or fibroses target. As described in the Company’s public filings … multiple drug candidates in clinical development and drug candidates designed to address chronic hepatitis B, coronaviruses and NASH targets. The Merck
S-1
EX-10.2
ALGS
Aligos Therapeutics Inc
25 Sep 20
IPO registration
5:27pm
to be genetic contributors of Hepatocellular Carcinoma (“HCC Gene Targets”), which gene targets Aligos shall identify to Luxna in writing at any time prior … of Nonalcoholic Steatohepatitis (“NASH Gene Target”), which gene targets Aligos shall identify to Luxna in writing at any time within eight (8) years
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 Nov 21
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
4:08pm
activities remain on track with dosing in healthy volunteers expected to begin in the fourth quarter of 2021.
Aligos has a broad CHB portfolio that targets
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
in the nonalcoholic steatohepatitis (NASH) oligonucleotide research collaboration with Merck with respect to the two undisclosed targets, utilizing Aligos
DRS
ALGS
Aligos Therapeutics Inc
26 Aug 20
Draft registration statement
12:00am
Capsid Assembly Modulator (“CAM”), and oligonucleotides (ASO and siRNA), each of which is designed against clinically validated targets … matter we can generate with these complementary modalities broadens the range of therapeutic targets we can address with our platforms, and provides us
S-1
mg0vte ehk
25 Sep 20
IPO registration
5:27pm
424B4
4yo2ecx8ro 2vorf7y
19 Oct 20
Prospectus supplement with pricing info
5:21pm
8-K
EX-99.1
aoq jltt9a4v9za
23 Mar 21
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:05pm
8-K
EX-99.1
maa4cm80 kgpq
5 Aug 21
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
4:06pm
10-K
e112533cktjc7cqu
23 Mar 21
Annual report
4:26pm
424B4
qmwspgvg62k
1 Jul 21
Prospectus supplement with pricing info
4:31pm
DRS
llqjst3
4 Jun 21
Draft registration statement
12:00am
S-1
EX-10.5
iju7phqwg6pvyew
25 Sep 20
IPO registration
5:27pm